» Articles » PMID: 39003313

Breast Cancer, Viruses, and Human Leukocyte Antigen (HLA)

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jul 13
PMID 39003313
Authors
Affiliations
Soon will be listed here.
Abstract

Several viruses have been implicated in breast cancer, including human herpes virus 4 (HHV4), human herpes virus 5 (HHV5), human papilloma virus (HPV), human JC polyoma virus (JCV), human endogenous retrovirus group K (HERVK), bovine leukemia virus (BLV) and mouse mammary tumor virus (MMTV). Human leukocyte antigen (HLA) is involved in virus elimination and has been shown to influence breast cancer protection/susceptibility. Here we investigated the hypothesis that the contribution of a virus to development of breast cancer would depend on the presence of the virus, which, in turn, would be inversely related to the success of its elimination. For that purpose, we estimated in silico predicted binding affinities (PBA) of proteins of the 7 viruses above to 127 common HLA alleles (69 Class I [HLA-I] and 58 Class II HLA-II]) and investigated the association of these binding affinities to the breast cancer-HLA (BC-HLA) immunogenetic profile of the same alleles. Using hierarchical tree clustering, we found that, for HLA-I, viruses BLV, JCV and MMTV were grouped with the BC-HLA, whereas, for HLA-II, viruses BLV, HERVK, HPV, JCV, and MMTV were grouped with BC-HLA. Finally, for both HLA classes, the average PBAs of the viruses grouped with the BC-HLA profile were significantly lower than those of the other, non BC-HLA associated viruses. Assuming that low PBAs are likely associated with slower viral elimination, these findings support the hypothesis that a defective/slower elimination and, hence, longer persistence and inefficient/delayed production of antibodies against them underlies the observed association of the low-PBA group with breast cancer.

Citing Articles

Immunogenetic profiles of 9 human herpes virus envelope glycoproteins.

Georgopoulos A, James L Sci Rep. 2024; 14(1):20924.

PMID: 39251790 PMC: 11385983. DOI: 10.1038/s41598-024-71558-1.

References
1.
Glenn W, Heng B, Delprado W, Iacopetta B, Whitaker N, Lawson J . Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. PLoS One. 2012; 7(11):e48788. PMC: 3501510. DOI: 10.1371/journal.pone.0048788. View

2.
Munoz N, Castellsague X, Berrington de Gonzalez A, Gissmann L . Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006; 24 Suppl 3:S3/1-10. DOI: 10.1016/j.vaccine.2006.05.115. View

3.
Stefanovic S, Wirtz R, Sutterlin M, Karic U, Schneeweiss A, Deutsch T . Cut-off Analysis of HLA-A and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer. Anticancer Res. 2023; 43(4):1449-1454. DOI: 10.21873/anticanres.16293. View

4.
Jhunjhunwala S, Hammer C, Delamarre L . Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021; 21(5):298-312. DOI: 10.1038/s41568-021-00339-z. View

5.
Chaudhuri S, Cariappa A, Tang M, Bell D, Haber D, Isselbacher K . Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000; 97(21):11451-4. PMC: 17220. DOI: 10.1073/pnas.97.21.11451. View